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PCLINICAL RESEARCH Cardiovascular Risk
Erectile Dysfunction and Later
Cardiovascular Disease in Men With Type 2 Diabetes
Prospective Cohort Study Based on the
ADVANCE (Action in Diabetes and Vascular Disease:
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Objectives The aim of this study was to examine the relationship between erectile problems in men and cardiovascular
disease (CVD) mortality.
Background Although there are plausible mechanisms linking erectile dysfunction (ED) with coronary heart disease (CHD)
and stroke, studies are scarce.
Methods In a cohort analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-
Release Controlled Evaluation) trial population, 6,304 men age 55 to 88 years with type 2 diabetes participated
in a baseline medical examination when inquiries were made about ED. Over 5 years of follow-up, during which
study members attended repeat clinical examinations, the presence of fatal and nonfatal CVD outcomes, cogni-
tive decline, and dementia was ascertained.
Results After adjusting for a range of covariates, including existing illness, psychological health, and classic CVD risk fac-
tors, relative to those who were free of the condition, baseline ED was associated with an elevated risk of all
CVD events (hazard ratio: 1.19; 95% confidence interval: 1.08 to 1.32), CHD (hazard ratio: 1.35; 95% confidence
interval: 1.16 to 1.56), and cerebrovascular disease (hazard ratio: 1.36; 95% confidence interval: 1.11 to 1.67).
Men who experienced ED at baseline and at 2-year follow-up had the highest risk for these outcomes.
Conclusions In this cohort of men with type 2 diabetes, ED was associated with a range of CVD events. (J Am Coll Cardiol 2010;
56:1908–13) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.067m
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November 30, 2010:1908–13 Erectile Dysfunction and Cardiovascular Diseaseascular (3–5). Thus, risk factors for erectile dysfunction (ED)
e.g., smoking, raised blood pressure, obesity) appear to be the
ame as those for cardiovascular disease (CVD) (3), and the
ccurrence of erectile dysfunction rises monotonically with a
rogressive clustering of these indexes.
Erectile dysfunction appears to be associated with in-
reased risk for clinical events of CVD (6,7), coronary heart
isease (CHD) (8–10), and stroke (9), but prospective
ohort studies, which provide the best observational evi-
ence of a relationship are very scarce. We address this
aucity of evidence by using data from cohort analyses of a
arge, well-characterized, randomized controlled trial.
ethods
he ADVANCE (Action in Diabetes and Vascular Dis-
ase: Preterax and Diamicron Modified-Release Controlled
valuation) trial, described in detail elsewhere (11), was
esigned to investigate the separate effects of routine blood
ressure lowering and intensive blood glucose control on
ascular outcomes in patients with existing type 2 diabetes.
n brief, from 2001 to 2003, 12,877 men and women age 55
o 88 years with type 2 diabetes and histories of major
acrovascular or microvascular disease, or at least 1 other
ardiovascular risk factor, were recruited from 215 centers in
Figure 1 Flow of Study Participants Through the ADVANCE Tria
Flow of participants into the ADVANCE (Action in Diabetes and Vascular Disease: P
who reported their erectile function and who had complete covariate data at basel
follow-up are provided in the last row. CHD  coronary heart disease.0 countries. After an initial “run-
n” phase, 11,140 subjects (6,407
en) were randomized using a
actorial design to perindopril-
ndapamide or placebo and to
ntensive blood glucose control
n the basis of gliclazide modi-
ed release or to standard blood
lucose control. The flow of pa-
ients through the study is depicted in Figure 1. For the
urposes of the present study, data from the trial were
nalyzed on the basis of a prospective cohort study design, as
e have done previously (12). Approval to conduct the trial
as obtained from the ethics committee of each study
enter; all participants provided written informed consent.
aseline examination. At study induction, participants
esponded to questionnaire inquiries and took part in a
edical examination. Glycosylated hemoglobin, blood cho-
esterol (and fractions), blood pressure, resting heart rate,
nd serum creatinine were measured using standard proto-
ols. Height and weight were used to derive body mass
ndex (kg/m2). Nurses administered a series of questions
egarding ethnicity, educational attainment, physical activ-
ty, alcohol intake, cigarette smoking habit, major chronic
Abbreviations
and Acronyms
CHD  coronary heart
disease
CVD  cardiovascular
disease
ED  erectile dysfunction
x and Diamicron Modified-Release Controlled Evaluation) trial, focusing on men
e causes and numbers of deaths and events in these men after 5 years ofl
retera
ine. Th
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Erectile Dysfunction and Cardiovascular Disease November 30, 2010:1908–13isease, assistance with activities of daily living, medications
sed to control diabetes (e.g., gliclazide modified release,
etformin) and related conditions (e.g., beta-blockers, thi-
zide). The presence of minor psychiatric disorders (anxiety
nd depression) was ascertained using the EQ-5D (13,14).
ognitive function was assessed using the Mini-Mental
tate Examination, on which low scores indicate impaired
erformance (15). Subjects with scores24, or in whom the
urse suspected dementia, were referred to a medically
ualified specialist for diagnosis of dementia according to
iagnostic and Statistical Manual of Mental Disorders
riteria (16), if applicable. To maintain accurate self-
eported information, those with either contemporaneous
r prior diagnoses of dementia did not enter the study.
urses also asked all male subjects whether they had ED
categorized as “yes” or “no”).
scertainment of CVD, dementia, and cognitive impair-
ent during follow-up. Fatal and nonfatal CVD out-
omes were ascertained using a variety of sources. Informa-
ion on cause of death (certification, autopsy report, clinical
otes) was scrutinized by the Endpoint Adjudication Com-
ittee and a coding made according to the 10th revision of
he International Classification of Diseases (17). For non-
atal outcomes, when applicable, clinical notes, computed
Erectile Dysfunction and Baseline Characteristic(n  6,304)Table 1 Erectile Dysfunctio and B seline C(n  6,304)
Variable
Age at baseline examination (yrs)
Age at completion of education (yrs)
Glycosylated hemoglobin (%)
Height (cm)
Body mass index (kg/m2)
Total blood cholesterol (mmol/l)
High-density lipoprotein blood cholesterol (mmol/l)
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
Resting heart rate (beats/min)
Serum creatinine (mol/l)
Cognitive function (MMSE score)
Quality of life (EQ-5D score)
Diabetes duration (yrs)
Number of occasions of exercise 15 min/week
Number of alcoholic drinks/week
Caucasian/European ethnicity
Current cigarette smokers
Use of metformin or beta-blockers
Require assistance with daily activities
History of major macrovascular disease*
History of major microvascular disease†
History of major diabetic disease
Results are expressed as mean SD or as n (%). *A history of major m
infarction, hospital admission for transient ischemic attack, hospi
revascularization, or amputation secondary to vascular disease. †A h
macroalbuminuria (urinary albumin/creatinine ratio 300 g/mg), p
edema, or blindness in 1 eye thought to be caused by diabetes.ADVANCE Action in Diabetes and Vascular Disease: Preterax and Diamicro
Examination.omographic and magnetic resonance imaging reports (for
uspected stroke), laboratory biomarkers (e.g., creatine ki-
ase, troponins) and electrocardiographic reports (for sus-
ected myocardial infarction) were used. A CHD event was
enoted by death due to this condition (including sudden
eath), nonfatal myocardial infarction, silent myocardial
nfarction, coronary revascularization, or hospital admission
or unstable angina (18). A cerebrovascular event was
efined as a death due to this condition or nonfatal stroke,
ransient ischemic attack, or subarachnoid hemorrhage (18).
he protocol used to identify dementia at follow-up was the
ame as that for baseline (described previously). Cognitive
ecline was defined as a reduction in Mini-Mental State
xamination score of 3 or more points compared with
aseline score.
tatistical analyses. Baseline data were missing for 103
en, resulting in an analytical sample of 6,304. Having first
etermined that the proportional hazards assumption had
ot been violated, Cox models were used to estimate hazard
atios, with accompanying 95% confidence intervals, to
ummarize the association between erectile function and the
arious health outcomes (19). Hazard ratios were first
omputed separately in the treatment and placebo groups.
ith no indication that treatment allocation modified the
Men in the ADVANCE Trialct ristics in Men in the ADVANCE Trial
Erectile Dysfunction
p Valuen  3,146) Yes (n  3,158)
4.8 6.3 67.0 6.4 0.001
9.8 7.4 19.0 7.2 0.001
7.4 1.5 7.5 1.50 0.004
1.2 7.0 171.2 7.3 0.843
7.8 4.5 28.2 4.9 0.005
5.0 1.1 4.9 1.1 0.002
.19 0.3 1.19 0.3 0.634
3.8 20.9 145.8 21.2 0.002
1.6 11.0 81.0 10.7 0.026
3.4 12.5 73.0 12.4 0.283
1.9 22.1 94.7 26.4 0.001
8.8 1.7 28.5 1.8 0.001
.86 0.2 0.82 0.2 0.001
7.5 6.2 8.5 6.7 0.001
4.0 6.3 3.3 5.6 0.001
4.5 9.7 5.0 9.8 0.057
52 (58.9%) 2,037 (64.5%) 0.001
04 (19.2%) 485 (15.4%) 0.001
10 (70.2%) 2,227 (70.5%) 0.814
67 (2.1%) 111 (3.5%) 0.001
60 (33.7%) 1,267 (40.1%) 0.001
80 (8.9%) 385 (12.2%) 0.001
83 (5.8%) 267 (8.5%) 0.001
scular disease was defined as any of the following: stroke, myocardial
ission for unstable angina, coronary revascularization, peripheral
f major microvascular disease was defined as any of the following:
tive diabetic retinopathy, retinal photocoagulation therapy, maculars inhara
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November 30, 2010:1908–13 Erectile Dysfunction and Cardiovascular Diseasessociation of ED with the outcomes (p for interaction
0.10), data were pooled, and all analyses were adjusted for
reatment.
In subgroup analyses of men who did not develop any of
he outcomes of interest between baseline and follow-up at
4 months (n  5,427), we examined the possibility that
ew erectile problems may be related to CVD and other
utcomes. On the basis of the dichotomous questionnaire
esponses from baseline and 24-month follow-up, we there-
ore derived 4 groups: men without erectile dysfunction at
ither time point (referent group), men who had erectile
roblems at baseline but reported no such dysfunction at
ollow-up, men who developed erectile dysfunction between
aseline and follow-up, and men who had ED at both
aseline and follow-up (“unrelenting” erectile dysfunction).
ll analyses were performed using SAS version 9.1 (SAS
nstitute Inc., Cary, North Carolina).
esults
n Table 1, we show the baseline characteristics of study
articipants according to erectile dysfunction status. One-
alf of the men in the ADVANCE trial (3,158 of 6,304)
eported ED at the baseline examination. With few excep-
ions, men with ED had less favorable levels of baseline
VD risk factors, morbidity, and drug use than those
eporting no such problems. However, although statistically
ignificant at conventional levels because of the large sample
ize, absolute differences in these characteristics between
en with and without ED were generally modest in
agnitude. Men with ED were older, were heavier, and had
ower cognitive function. These men were also more likely
o have chronic ill health as indexed by a range of baseline
ndexes. Although men with ED were also less likely to be
hysically active, contrarily, they were less likely to smoke
nd had lower total blood cholesterol, and diastolic blood
ressure.
During a mean of 5 years of follow-up, there were 695
eaths from any cause, 1,579 fatal and nonfatal CVD
vents, 773 fatal and nonfatal CHD events, 411 fatal and
onfatal cerebrovascular disease events, 58 incident cases of
ementia, and 1,013 cases of cognitive decline. In Table 2
e show the relation between ED and a range of health
utcomes. Considering first the outcomes of total mortality,
VD, CHD, and cerebrovascular disease, it is unsurprising
hat, with both exposure and outcomes strongly age related,
ontrolling for age had a marked attenuating effect on all the
azard ratios. In analysis adjusted for age and treatment
roup, relative to men who were free of erectile problems at
aseline, those with ED experienced an elevated risk of
etween 34% and 53%. Adjusting for existing illness and
edication led to some attenuation in these effects. Of the
VD risk factors, adding the psychological indexes (quality
f life and cognitive function) to the multivariate model
ppeared to explain some of the effect of erectile problems
n total mortality, all CVD events, and all CHD and Ha T
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Erectile Dysfunction and Cardiovascular Disease November 30, 2010:1908–13erebrovascular events. After multiple adjustment for a
ange of baseline characteristics, some attenuation was again
pparent, but with the exception of total mortality, gradients
eld at conventional levels of statistical significance. Erectile
roblems were associated with increased risk for both these
utcomes, but most effect estimates were not statistically
ignificant at conventional levels.
Finally, we examined the association of change in erectile
unction status between baseline and 24-month follow-up
ith the future risk for new events and deaths in a
ubsample of the population who remained free of these
utcomes during this 2-year period (Table 3). For total
ortality, CVD, CHD, and cerebrovascular disease, as
nticipated, the highest rates were evident in men whose
ymptoms of ED persisted between baseline and follow-up
4 months later, although the confidence intervals for total
ortality included unity. Similar patterns of association
ere apparent for dementia and cognitive decline, although
he number of events for the former was very low.
iscussion
he main finding of this study was that ED was associated
ith total mortality, CVD, CHD, and cerebrovascular
isease. Although controlling for the classic CVD risk
actors (smoking, and raised blood pressure and blood
holesterol) had little impact on the magnitude of these
radients, marked attenuation was apparent when other
ovariates, such as existing illness, medication, and psycho-
ogical distress, were added to the multivariate model.
owever, statistical significance at conventional levels was
ypically retained.
rior studies. Our finding that ED apparently confers an
ncreased risk for CHD is supported in the few other prospec-
ive cohort studies conducted, which were generally less well
ontrolled than our own and, with few exceptions (9), mark-
dly smaller in scale. To our knowledge, only 1 other study
xamined the role of erectile problems in the etiology of stroke
9), and that too found a positive association.
lausible explanations. Potential noncausal explanations for
he apparent impact of ED on these chronic CVD outcomes
nclude bias and confounding. In the present study, dropout by
he original study members was very low. We also adjusted for
ultiple Adjusted Hazard Ratios (95% Confidence Intervals) for the Retween Baseline and 24-Month Follow-Up With Selected Health OutcTable 3 Multiple Adjusted Hazard Ratios (95% Confi ence Int rvaBetween Baseline and 24-Month Follow-Up With Selected
ED at
Baseline
ED at
24 Months n
Total Mortality
(n  388)
CVD
(n  965)
No No 1,964 1.00 (reference) 1.00
Yes No 814 1.05 (0.75–1.48) 1.24 (1.01–1.5
No Yes 618 1.08 (0.74–1.56) 0.98 (0.78–1.2
Yes Yes 2031 1.29 (1.00–1.66) 1.28 (1.09–1.5
p value for trend — 0.0419 0.0081
ultiple adjustment as in Table 2. Analytical sample was based on a subgroup of men who did n
Abbreviations as in Table 2.very wide range of confounding variables, and these gradi- tnts, although attenuated, remained statistically significant at
onventional levels. The effect that remained for ED in relation
o the various outcomes is probably too large to be explained by
esidual confounding in this well-characterized study, but we of
ourse cannot rule out the explanatory power of unmeasured or
nknown covariates.
The absence of convincing alternative explanations for these
ssociations raises the possibility of a real effect of ED on the
utcomes herein. One obvious possibility is that ED results
rom peripheral neuropathy, that is, damage to nerves of the
eripheral nervous system. Another option is that, given that
he penis is an extensively vascularized organ, erections are, to
large degree, vascular events. With the penile (1 to 2 mm)
rteries being substantially narrower than the coronary (3 to 4
m), carotid (5 to 7 mm), and femoral (6 to 8 mm) arteries
20), as described, for the same quantity of atherosclerosis,
rectile dysfunction may precede a similar vascular event in the
eart.
tudy strengths and limitations. Although the present
tudy has a number of strengths, including the detailed
ange of covariates collected, the large sample size, repeat
easurement of ED, and the fact that it is the first to
xamine links with dementia and cognitive function, it of
ourse also has its limitations. Although it may be testimony
o the robustness of the relation that a very simple question
egarding erectile dysfunction was linked to CVD, we did
ot capture information on the severity of exposure by, for
nstance, using the International Index of Erectile Dysfunc-
ion (21). This would have allowed us to examine dose-
esponse effects.
onclusions
e demonstrated associations between ED and a range of
VD outcomes. However, rather than having a direct,
ndependent effect on CVD, it is more likely that erectile
ysfunction is a marker of CVD risk.
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